Uniplan Investment Counsel Inc. Has $1.61 Million Position in Royalty Pharma PLC $RPRX

Key Points

• Uniplan Investment Counsel Inc. increased its holdings in Royalty Pharma PLC by 29.8%, owning 51,838 shares valued at approximately $1.6 million.
• Royalty Pharma recently announced a quarterly dividend of $0.22 per share, which will be paid on September 10th, representing an annual yield of 2.4%.
• Wall Street analysts have a consensus rating of “Buy” for Royalty Pharma, with an average target price of $48.00 following raises in price targets by multiple brokerages.

Uniplan Investment Counsel Inc. raised its stake in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 29.8% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 51,838 shares of the biopharmaceutical company's stock after buying an additional 11,904 shares during the quarter. Uniplan Investment Counsel Inc.'s holdings in Royalty Pharma were worth $1,614,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of RPRX. Victory Capital Management Inc. lifted its stake in Royalty Pharma by 270.4% in the first quarter. Victory Capital Management Inc. now owns 3,623,134 shares of the biopharmaceutical company's stock valued at $112,788,000 after buying an additional 2,644,923 shares in the last quarter. Los Angeles Capital Management LLC lifted its stake in Royalty Pharma by 2,543.7% in the first quarter. Los Angeles Capital Management LLC now owns 1,081,128 shares of the biopharmaceutical company's stock valued at $33,656,000 after buying an additional 1,040,234 shares in the last quarter. Wedge Capital Management L L P NC bought a new position in Royalty Pharma in the first quarter valued at approximately $31,591,000. Bank of America Corp DE lifted its stake in Royalty Pharma by 46.7% in the fourth quarter. Bank of America Corp DE now owns 2,985,585 shares of the biopharmaceutical company's stock valued at $76,162,000 after buying an additional 950,880 shares in the last quarter. Finally, Jupiter Asset Management Ltd. lifted its stake in Royalty Pharma by 462.1% in the first quarter. Jupiter Asset Management Ltd. now owns 1,090,591 shares of the biopharmaceutical company's stock valued at $33,950,000 after buying an additional 896,555 shares in the last quarter. Institutional investors own 54.35% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on RPRX shares. Morgan Stanley boosted their price objective on shares of Royalty Pharma from $51.00 to $54.00 and gave the stock an "overweight" rating in a research report on Thursday, July 10th. Citigroup boosted their price objective on shares of Royalty Pharma from $40.00 to $42.00 and gave the stock a "buy" rating in a research report on Tuesday, July 22nd. Finally, Wall Street Zen raised shares of Royalty Pharma from a "hold" rating to a "buy" rating in a research report on Saturday, August 30th. One analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $48.00.

Royalty Pharma Stock Performance

NASDAQ RPRX traded down $0.39 on Friday, hitting $36.31. 2,300,710 shares of the stock were exchanged, compared to its average volume of 4,329,303. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.26 and a quick ratio of 1.26. The business's fifty day moving average is $36.36 and its 200 day moving average is $34.27. Royalty Pharma PLC has a 52 week low of $24.05 and a 52 week high of $38.00. The company has a market capitalization of $21.17 billion, a PE ratio of 21.00, a P/E/G ratio of 2.26 and a beta of 0.58.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.04. Royalty Pharma had a net margin of 44.23% and a return on equity of 25.54%. The firm had revenue of $578.67 million for the quarter, compared to analyst estimates of $750.06 million. Research analysts anticipate that Royalty Pharma PLC will post 4.49 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th were issued a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 2.4%. The ex-dividend date was Friday, August 15th. Royalty Pharma's payout ratio is currently 50.87%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.